- Home
- CABA vs SMTI Comparison
CABA vs SMTI Comparison
Compare CABA & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- SMTI
- Stock Information
- Founded
- CABA 2017
- SMTI 1982
- Country
- CABA United States
- SMTI United States
- Employees
- CABA N/A
- SMTI N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- SMTI Medical/Dental Instruments
- Sector
- CABA Health Care
- SMTI Health Care
- Exchange
- CABA Nasdaq
- SMTI Nasdaq
- Market Cap
- CABA 233.2M
- SMTI 192.5M
- IPO Year
- CABA 2019
- SMTI N/A
- Fundamental
- Price
- CABA $2.32
- SMTI $22.32
- Analyst Decision
- CABA Strong Buy
- SMTI Strong Buy
- Analyst Count
- CABA 8
- SMTI 2
- Target Price
- CABA $13.50
- SMTI $41.00
- AVG Volume (30 Days)
- CABA 5.3M
- SMTI 55.2K
- Earning Date
- CABA 11-10-2025
- SMTI 11-12-2025
- Dividend Yield
- CABA N/A
- SMTI N/A
- EPS Growth
- CABA N/A
- SMTI N/A
- EPS
- CABA N/A
- SMTI N/A
- Revenue
- CABA N/A
- SMTI $101,877,532.00
- Revenue This Year
- CABA N/A
- SMTI $24.49
- Revenue Next Year
- CABA N/A
- SMTI $14.43
- P/E Ratio
- CABA N/A
- SMTI N/A
- Revenue Growth
- CABA N/A
- SMTI 30.52
- 52 Week Low
- CABA $0.99
- SMTI $19.10
- 52 Week High
- CABA $5.46
- SMTI $38.75
- Technical
- Relative Strength Index (RSI)
- CABA 44.66
- SMTI 30.14
- Support Level
- CABA $2.30
- SMTI $19.10
- Resistance Level
- CABA $2.67
- SMTI $29.20
- Average True Range (ATR)
- CABA 0.33
- SMTI 1.70
- MACD
- CABA -0.07
- SMTI -0.87
- Stochastic Oscillator
- CABA 8.05
- SMTI 20.59
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.